Simcere to receive a $15M up front, ~$492M in development, commercial & sales milestones in multiple indications along with royalties
Almirall to get an exclusive right to develop & commercialize SIM0278 for all indications outside of the Greater China region (Mainland China, Hong Kong, Macau & Taiwan). Simcere holds all rights within Greater China
SIM0278 is an interleukin 2 mutant fusion protein (IL-2 mu-Fc) that uses the protein engineering platform of Simcere to stimulate regulatory T cells & is designed to treat immunological diseases. In multiple preclinical disease models, SIM0278 showed a better PK profile & selective activation of Treg cells with no activation of effector T cells or NK cells to restore immunological balance
Ref: PRNewswire | Image: Simcere
